Developments in clinical islet, liver thoracic, kidney and pancreas transplantation in the last 5 years

American Journal of Transplantation

Volumn 6, Issue 8, 2006, Pages 1759-1767

  Feng, S ^a   Barr, M ^b   Roberts, J ^a   Oberbauer, R ^c   Kaplan, B ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Allocation policy; MELD; Minimization protocols; Recurrent hepatitis C; Sirolimus; Steroid avoidance

Indexed keywords

15 DEOXYSPERGUALIN; 2 CYANO 3 HYDROXY N [4 (TRIFLUOROMETHYL)PHENYL] 6 HEPTYNAMIDE; ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CIDOFOVIR; CORTICOSTEROID; CYCLOSPORIN; EVEROLIMUS; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERFERON; LEFLUNOMIDE; MALONONITRILAMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; QUINOLONE DERIVATIVE; RAPAMYCIN; RITUXIMAB; STEROID; TACROLIMUS; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; BLOOD GROUP ABO INCOMPATIBILITY; CLINICAL TRIAL; CYTOMEGALOVIRUS INFECTION; DEVICE; GASTROINTESTINAL SYMPTOM; GRAFT RECIPIENT; GRAFT REJECTION; HEALTH CARE POLICY; HEART ASSIST DEVICE; HEART TRANSPLANTATION; HEPATITIS C; HEPATITIS C VIRUS; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER DISEASE; LIVER TRANSPLANTATION; LIVING DONOR; LONGEVITY; LUNG TRANSPLANTATION; MULTIPLE ORGAN FAILURE; NEPHROTOXICITY; ORGAN TRANSPLANTATION; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; POLYOMA VIRUS; PRIORITY JOURNAL; SHORT SURVEY; SURVIVAL; VASCULAR DISEASE; VIREMIA; VIRUS INFECTION;

EID: 33745787263     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2006.01402.x     Document Type: Short Survey

References (63)

1. Shapiro AMJ, Lakey JRT, Ryan EA et al. Islet transplantation in seven patients with Type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230-238.
2. Shapiro AM, Lakey JR, Paty BW, Senior PA, Bigam DL, Ryan EA. Strategic opportunities in clinical islet transplantation. Transplant 2005; 79: 1304-1307.
3. Shapiro AMJ, Ricordi C, Hering BJ. Edmonton's islet success has indeed been replicated elsewhere. Lancet 2003; 362: 1242.
4. Froud T, Ricordi C, Baidal DA et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosuppression: Miami experience. Am J Transplant 2005; 5: 2037-2046.
5. Hering BJ, Kandaswamy R, Ansite JD et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830-835.
6. Ryan EA, Paty BW, Senior PA et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060-2069.
7. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31: 864-871.
8. Kamath PS, Wiesner RH, Malinchoc M et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33: 464-470.
9. Wiesner R, Edwards E, Freeman R et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124: 91-96.
10. Freeman RB, Wiesner RH, Edwards E, Harper A, Merion R, Wolfe R. Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10: 7-15.
11. Freeman RB, Jr., Wiesner RH, Roberts JP, McDiarmid S, Dykstra DM, Merion RM. Improving liver allocation: MELD and PELD. Am J Transplant 2004; 4 (Suppl 9): 114-131.
12. Wachs ME, Bak TE, Karrer FM et al. Adult living donor liver transplantation using a right hepatic lobe. Transplant 1998; 66: 1313-1316.
13. Marcos A, Fisher RA, Ham JM et al. Right lobe living donor liver transplantation. Transplant 1999; 68: 798-803.
14. Brown RS, Jr., Russo MW, Lai M et al. A survey of liver transplantation from living adult donors in the United States. N Engl J Med 2003; 348: 818-825.
15. Lo CM. Complications and long-term outcome of living liver donors: A survey of 1,508 cases in five Asian centers. Transplant 2003; 75 (3 Suppl): S12-S15.
16. Pomfret EA. Early and late complications in the right-lobe adult living donor. Liver Transpl 2003; 9(10 Suppl 2): S45-S49.
17. Lo CM, Fan ST, Liu CL et al. Lessons learned from one hundred right lobe living donor liver transplants. Ann Surg 2004; 240: 151-158.
18. Malago M, Testa G, Frilling A et al. Right living donor liver transplantation: An option for adult patients: Single institution experience with 74 patients. Ann Surg 2003; 238: 853-862.
19. Maluf DG, Stravitz RT, Cotterell AH et al. Adult living donor versus deceased donor liver transplantation: A 6-year single center experience. Am J Transplant 2005; 5: 149-156.
20. Pomposelli JJ, Verbesey J, Simpson MA et al. Improved survival after live donor adult liver transplantation (LDALT) using right lobe grafts: Program experience and lessons learned. Am J Transplant 2006; 6: 589-598.
21. Olthoff KM, Merion RM, Ghobrial RM et al. Outcomes of 385 adult-to-adult living donor liver transplant recipients: A report from the A2ALL Consortium. Ann Surg 2005; 242: 314-323, discussion.
22. Shiffman ML, Saab S, Feng S et al. Liver and intestine transplantation in the United States: 1995-2004. Am J Transplant 2006; 6: 1170-1187.
23. Shergill AK, Khalili M, Straley S et al. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124.
24. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931-940.
25. Eisen HJ, Tuzcu EM, Dorent R et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847-858.
26. Keogh A, Richardson M, Ruygrok P et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: A randomized clinical trial. Circulation 2004; 110: 2694-2700.
27. Kobashigawa JA, Tobis JM, Starling RC et al. Multicenter intravascular ultrasound validation study among heart transplant recipients: Outcomes after five years. J Am Coll Cardiol 2005; 45: 1532-1537.
28. Rose EA, Gelijns AC, Moskowitz AJ et al. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med 2001; 345: 1435-1443.
29. Barr ML, Bourge RC, Orens JB et al. Thoracic organ transplantation in the United States, 1994-2003. Am J Transplant 2005; 5 (4 Pt 2): 934-949.
30. Meier-Kriesche HU, Schold JD, Kaplan B. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289-1295.
31. Vincenti F, Larsen C, Durrbach A et al. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770-781.
32. Flechner SM, Friend PJ, Brockmann J et al. Alemtuzumab induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005; 5: 3009-3014.
33. Kirk AD, Mannon RB, Kleiner DE et al. Results from a human renal allograft tolerance trial evaluating T-cell depletion with alemtuzumab combined with deoxyspergualin. Transplantation 2005; 80: 1051-1059.
34. Shapiro R, Basu A, Tan H et al. Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505-515.
35. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: Comparison with basiliximab induction - Long-term results. Am J Transplant 2005; 5: 2539-2548.
36. Knechtle SJ, Pirsch JD, Fechner H et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: Results of a pilot study. Am J Transplant 2003; 3: 722-730.
37. Becker YT, Becker BN, Pirsch JD, Sollinger HW. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004; 4: 996-1001.
38. Budde K, Curtis J, Knoll G et al. Enteric-coated mycophenolate sodium can be safely administered in maintenance renal transplant patients: Results of a 1-year study. Am J Transplant 2004; 4: 237-243.
39. Salvadori M, Holzer H, de Mattos A et al. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2004; 4: 231-236.
40. Vanrenterghem Y, van Hooff JP, Klinger M et al. The effects of FK778 in combination with tacrolimus and steroids: A phase II multicenter study in renal transplant patients. Transplant 2004; 78: 9-14.
41. Kaplan B, Schold J, Srinivas T et al. Effect of sirolimus withdrawal in patients with deteriorating renal function. Am J Transplant 2004; 4: 1709-1712.
42. Oberbauer R, Segoloni G, Campistol JM et al. Early cyclosporine withdrawal from a sirolimus-based regimen results in better renal allograft survival and renal function at 48 months after transplantation. Transplant Int 2005; 18: 22-28.
43. Mota A, Arias M, Taskinen EI et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953-961.
44. Flechner SM, Kurian SM, Solez K et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years. Am J Transplant 2004; 4: 1776-1785.
45. Larson TS, Dean PG, Stegall MD et al. Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6: 514-522.
46. Hazzan M, Labalette M, Copin MC et al. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: Results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16: 2509-2516.
47. Pascual J, Quereda C, Zamora J, Hernandez D. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: A meta-analysis of randomized, controlled trials. Transplant 2004; 78: 1548-1556.
48. Matas AJ, Kandaswamy R, Gillingham KJ et al. Prednisone-free maintenance immunosuppression-a 5-year experience. Am J Transplant 2005; 5: 2473-2478.
49. Anil Kumar MS, Moritz MJ, Saaed MI et al. Avoidance of chronic steroid therapy in african american kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005; 5: 1976-1985.
50. Feucht HE, Schneeberger H, Hillebrand G et al. Capillary deposition of C4d complement fragment and early renal graft loss. Kidney Int 1993; 43: 1333-1338.
51. Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria - An addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708-714.
52. Moll S, Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005; 5: 2611-2618.
53. Hippen BE, DeMattos A, Cook WJ, Kew CE, Gaston RS. Association of CD20+ infiltrates with poorer clinical outcomes in acute cellular rejection of renal allografts. Am J Transplant 2005; 5: 2248-2252.
54. Mauiyyedi S, Crespo M, Collins AB et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002; 13: 779-787.
55. Regele H, Bohmig GA, Habicht A et al. Capillary deposition of complement split product C4d in renal allografts is associated with basement membrane injury in peritubular and glomerular capillaries: A contribution of humoral immunity to chronic allograft rejection. J Am Soc Nephrol 2002; 13: 2371-2380.
56. Takahashi K, Saito K, Takahara S et al. Excellent long-term outcome of ABO-incompatible living donor kidney transplantation in Japan. Am J Transplant 2004; 4: 1089-1096.
57. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant 2004; 4: 1357-1360.
58. Hirsch HH, Brennan DC, Drachenberg CB et al. Polyomavirus-associated nephropathy in renal transplantation: Interdisciplinary analyses and recommendations. Transplant 2005; 79: 1277-1286.
59. Vasudev B, Hariharan S, Hussain SA, Zhu YR, Bresnahan BA, Cohen EP. BK virus nephritis: Risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68: 1834-1839.
60. Kaufman DB, Leventhal JR, Gallon LG, Parker MA. Alemtuzumab induction and prednisone-free maintenance immunotherapy in simultaneous pancreas-kidney transplantation comparison with rabbit antithymocyte globulin induction - Long-term results. Am J Transplant 2006; 6: 331-339.
61. Venstrom JM, McBride MA, Rother KI, Hirshberg B, Orchard TJ, Harlan DM. Survival after pancreas transplantation in patients with diabetes and preserved kidney function. JAMA 2003; 290: 2817-2823.
62. Gruessner RW, Sutherland DE, Gruessner AC. Mortality assessment for pancreas transplants. Am J Transplant 2004; 4: 2018-2026.
63. Lake JR, Shorr JS, Steffen BJ, Chu AH, Gordon RD, Wiesner RH. Differential effects of donor age in liver transplant recipients infected with hepatitis B, hepatitis C and without viral hepatitis. Am J Transplant 2005; 5: 549-557.